Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
9th Nov 20233:49 pmRNSResult of General Meeting
13th Oct 20234:56 pmRNSPublication of a Prospectus
13th Oct 202310:17 amRNSDirector/PDMR Shareholding
13th Oct 202310:15 amRNSIssue of Equity - Dividend Investment Scheme
6th Oct 20232:39 pmRNSStatement re Dividend Investment Scheme
8th Sep 20235:01 pmRNSTransaction in Own Shares-Corrective announcement
7th Sep 20233:35 pmRNSTransaction in Own Shares
30th Aug 20232:02 pmRNSHalf-year Report
17th Aug 20233:26 pmRNSStatement re NAV and Interim Dividend
12th Jul 20234:09 pmRNSHolding(s) in Company
10th Jul 20235:06 pmRNSHolding(s) in Company
2nd Jun 202310:05 amRNSDirector/PDMR Shareholding
2nd Jun 20239:43 amRNSIssue of Equity
24th May 20235:10 pmRNSTransaction in Own Shares
23rd May 202310:18 amRNSDirector/PDMR Shareholding
23rd May 202310:17 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20233:38 pmRNSNet Asset Value(s) - Dividend Investment Scheme
11th May 20233:01 pmRNSResult of AGM
11th May 20232:20 pmRNSNet Asset Value(s)
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
13th Apr 20237:00 amRNSAnnual Financial Report
5th Apr 202312:36 pmRNSDirector/PDMR Shareholding
5th Apr 202312:30 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
21st Mar 20234:08 pmRNSTransaction in Own Shares
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:11 pmRNSUnaudited NAV and Proposed Final Dividend
21st Feb 20233:10 pmRNSUnaudited Net Asset Value, Proposed Final Dividend
16th Feb 20237:00 amRNSStatement re Offer for Subscription
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 202310:17 amRNSDirector/PDMR Shareholding
8th Feb 20239:44 amRNSIssue of Equity
3rd Feb 20233:12 pmRNSProvisional Net Asset Value
23rd Nov 20224:53 pmRNSTransaction in Own Shares
10th Nov 20223:33 pmRNSNet Asset Value(s)
9th Nov 20223:02 pmRNSResult of General Meeting
7th Oct 20224:28 pmRNSPublication of a Prospectus
7th Oct 20229:58 amRNSDirector/PDMR Shareholding
7th Oct 20229:51 amRNSIssue of Equity
4th Oct 20223:30 pmRNSChange of Auditor
3rd Oct 20223:08 pmRNSStatement re Dividend Investment Scheme
6th Sep 20224:48 pmRNSTransaction in Own Shares
2nd Sep 20223:30 pmRNSHalf-year Report
19th Aug 202210:47 amRNSStatement re NAV and Interim Dividend
14th Jul 20229:33 amRNSDirectorate Change
8th Jul 20223:28 pmRNSStatement re Joint Offers for Subscription
24th Jun 20224:13 pmRNSDirectorate Change
9th Jun 20224:18 pmRNSTransaction in Own Shares
6th Jun 20222:15 pmRNSIssue of Equity
20th May 202210:09 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.